-
10532-25A potent, selective CysLT2 receptor antagonist that inhibits radioligand binding of LTD4 to CysLT2 and CysLT1 receptor cell lines with IC50 values of 35 and >10,000 nM, respectively.
-
10532-5A potent, selective CysLT2 receptor antagonist that inhibits radioligand binding of LTD4 to CysLT2 and CysLT1 receptor cell lines with IC50 values of 35 and >10,000 nM, respectively.
-
17448-1A selective inhibitor of BAZ2A (Kd = 109 nM IC<sub>50</sub> = 130 nM) and BAZ2B (Kd = 170 nM IC<sub>50</sub> = 180 nM) bromodomains.
-
17448-10A selective inhibitor of BAZ2A (Kd = 109 nM IC<sub>50</sub> = 130 nM) and BAZ2B (Kd = 170 nM IC<sub>50</sub> = 180 nM) bromodomains.
-
17448-25A selective inhibitor of BAZ2A (Kd = 109 nM IC<sub>50</sub> = 130 nM) and BAZ2B (Kd = 170 nM IC<sub>50</sub> = 180 nM) bromodomains.
-
17448-5A selective inhibitor of BAZ2A (Kd = 109 nM IC<sub>50</sub> = 130 nM) and BAZ2B (Kd = 170 nM IC<sub>50</sub> = 180 nM) bromodomains.
-
15005-10An indole-based SERM that binds to both ER&alpha (IC<sub>50</sub> = 26 nM) and ER&beta (IC<sub>50</sub> = 99 nM) antagonizes 17&beta-estradiol-dependent and hormone-independent growth of breast cancer cell proliferation (80% reduction with 10
-
15005-25An indole-based SERM that binds to both ER&alpha (IC<sub>50</sub> = 26 nM) and ER&beta (IC<sub>50</sub> = 99 nM) antagonizes 17&beta-estradiol-dependent and hormone-independent growth of breast cancer cell proliferation (80% reduction with 10
-
15005-5An indole-based SERM that binds to both ER&alpha (IC<sub>50</sub> = 26 nM) and ER&beta (IC<sub>50</sub> = 99 nM) antagonizes 17&beta-estradiol-dependent and hormone-independent growth of breast cancer cell proliferation (80% reduction with 10
-
15005-50An indole-based SERM that binds to both ER&alpha (IC<sub>50</sub> = 26 nM) and ER&beta (IC<sub>50</sub> = 99 nM) antagonizes 17&beta-estradiol-dependent and hormone-independent growth of breast cancer cell proliferation (80% reduction with 10
-
17079-1A Cl-amidine derivative with greater cellular potency against PAD4 activity (EC<sub>50</sub> = 8.8 µM, vs.
-
17079-5A Cl-amidine derivative with greater cellular potency against PAD4 activity (EC<sub>50</sub> = 8.8 µM, vs.